Announcement Details

View all announcements

Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc

(“Hemogenyx Pharmaceuticals” or the “Company”)

 

Result of Annual General Meeting

 

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.

AGM Voting Results

Ordinary Resolutions Votes for % of votes cast for Votes Against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2)
1. To adopt the 2020 Annual Report and Accounts​ 126,557,317 99.87% 168,193 0.13% 126,725,510 12.93% 289,150
2. To approve the Directors’ Remuneration Policy​ 125,619,330 99.07% 1,177,033 0.93% 126,796,363 12.94% 218,297
3. To approve the Directors’ Remuneration Report​ 125,638,477 99.07% 1,177,033 0.93% 126,815,510 12.94% 199,150
4. To reappoint the Company’s auditor​ 126,528,170 99.87% 168,193 0.13% 126,696,363 12.93% 318,297
5. To authorise the Audit Committee to determine the auditor’s remuneration​ 126,356,107 99.72% 350,256 0.28% 126,706,363 12.93% 308,297
6. To re-elect Sir Marc Feldmann as a director of the Company 125,895,121 99.28% 911,242 0.72% 126,806,363 12.94% 208,297
7. To authorise the Directors to allot equity securities​ 125,663,209 99.11% 1,133,154 0.89% 126,796,363 12.94% 218,297
Special Resolutions Votes for % of votes cast for Votes against % of votes cast against Total votes cast Total votes cast as % of ISC (1) Votes with-held (2)
8. To disapply pre-emption provisions​ 123,047,368 97.04% 3,748,995 2.96% 126,796,363 12.94% 218,297
9. To adopt new Articles of Association​ 125,663,209 99.27% 923,154 0.73% 126,586,363 12.92% 428,297
10. To adopt new Articles of Association​ 126,014,268 99.36% 811,242 0.64% 126,825,510 12.94% 189,150
  1. The Company’s issued share capital (“ISC”) on 23 June 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 979,749,321 ordinary shares.
  2. A ‘vote withheld’ in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

 

Enquiries:

Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

 

View all announcements